JP2020517615A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517615A5
JP2020517615A5 JP2019556626A JP2019556626A JP2020517615A5 JP 2020517615 A5 JP2020517615 A5 JP 2020517615A5 JP 2019556626 A JP2019556626 A JP 2019556626A JP 2019556626 A JP2019556626 A JP 2019556626A JP 2020517615 A5 JP2020517615 A5 JP 2020517615A5
Authority
JP
Japan
Prior art keywords
scleroderma
cells
polynucleotide
vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019556626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517615A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028551 external-priority patent/WO2018195410A1/en
Publication of JP2020517615A publication Critical patent/JP2020517615A/ja
Publication of JP2020517615A5 publication Critical patent/JP2020517615A5/ja
Ceased legal-status Critical Current

Links

JP2019556626A 2017-04-21 2018-04-20 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達 Ceased JP2020517615A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762488207P 2017-04-21 2017-04-21
US62/488,207 2017-04-21
US201762512382P 2017-05-30 2017-05-30
US62/512,382 2017-05-30
PCT/US2018/028551 WO2018195410A1 (en) 2017-04-21 2018-04-20 Delivery of autologous cells comprising matrix metalloproteinase for treatment of scleroderma

Publications (2)

Publication Number Publication Date
JP2020517615A JP2020517615A (ja) 2020-06-18
JP2020517615A5 true JP2020517615A5 (cg-RX-API-DMAC7.html) 2023-06-16

Family

ID=63856118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556626A Ceased JP2020517615A (ja) 2017-04-21 2018-04-20 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達

Country Status (9)

Country Link
US (1) US20200129561A1 (cg-RX-API-DMAC7.html)
EP (1) EP3612554A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020517615A (cg-RX-API-DMAC7.html)
KR (1) KR102544139B1 (cg-RX-API-DMAC7.html)
CN (1) CN110770249B (cg-RX-API-DMAC7.html)
AU (1) AU2018254555A1 (cg-RX-API-DMAC7.html)
CA (1) CA3060099A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909440UA (cg-RX-API-DMAC7.html)
WO (1) WO2018195410A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4380601A4 (en) * 2021-08-06 2025-06-25 Trujillo, Charles, Nathan SYSTEM AND METHOD FOR TREATING OR PREVENTING RESPIRATORY FAILURE WITH AEROSOLIZED COLLAGENASE
CN114921446B (zh) * 2022-06-08 2025-08-29 宁波市健康口腔医学研究院 一种口腔癌标志物线性表位融合肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
WO2009116860A1 (en) * 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用
EP2550359B1 (en) * 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
CN103370340B (zh) * 2010-12-02 2016-08-31 庆北大学校产学协力团 包含dhFas-1结构域和MMP底物的融合肽及其在预防和治疗类风湿性关节炎中的应用
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
EP4050020A1 (en) * 2014-03-11 2022-08-31 University of Florida Research Foundation, Inc. Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
SG11201702295UA (en) * 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12

Similar Documents

Publication Publication Date Title
JP7590724B2 (ja) 炎症性腸疾患の治療薬
Nissen et al. Increased turnover of arterial collagen in hypertensive rats.
CN1496271B (zh) 伴随有aop-1基因或aop-1的表达减少的疾病的治疗方法以及该疾病的治疗药
ES2622877T3 (es) Tratamiento para la obesidad
CN102766204B (zh) 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
Qi et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice
US20190358144A1 (en) Compositions comprising peptide wkdeagkplvk
US10213488B2 (en) Delivery of therapeutic agents by a collagen binding protein
KR20120101617A (ko) 알부민과 레티놀 결합 단백질의 융합 단백질
AU2013202269A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
Zafar et al. Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure development
Goldspink et al. Growth factors, muscle function and doping
WO2004108748A3 (en) Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
Zhong et al. Krüppel-like transcription factor 14 alleviates alveolar epithelial cell senescence by inhibiting endoplasmic reticulum stress in pulmonaryfibrosis
Nagler et al. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone
CN111944035B (zh) Fgf4及其应用
AU2014233219B2 (en) Methods for treatment of nephrotic syndrome and related conditions
AU2008347208B2 (en) Treatment of fibroses and liver disorders
CN110770249B (zh) 递送包含基质金属蛋白酶的自体细胞用于治疗硬皮病
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
Herrmann et al. Transforming growth factor-α enhances stem cell-mediated postischemic myocardial protection
KR20220015638A (ko) 염증성 질환의 예방 또는 치료용 조성물 및 이의 용도
US20180066027A1 (en) Protamine in treatment of neuronal injuries
JP2008231036A (ja) ポリペプチドを有効成分とする自己免疫性皮膚疾患治療薬